Drug Profile
ARQ 761
Alternative Names: ARQ-761Latest Information Update: 20 Jan 2020
Price :
$50
*
At a glance
- Originator ArQule
- Developer Merck & Co; University of Texas Southwestern Medical Center
- Class Antineoplastics; Naphthoquinones; Small molecules
- Mechanism of Action E2F1 transcription factor stimulants; NQO1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pancreatic cancer
- Phase I/II Solid tumours
Most Recent Events
- 16 Jan 2020 ArQule has been acquired and merged into Merck & Co
- 30 Aug 2018 Phase-I/II clinical trials in Solid tumours (Late-stage disease) in USA (IV) (ArQule Pipeline, August 2018)
- 02 Jul 2018 University of Texas Southwestern Medical Center plans a phase I trial for Solid tumours (Combination therapy) in August 2018 , (NCT03575078)